In a University of California, San Francisco research study, (published in the journal Cell) found cancer immunotherapy drugs hold great promise but still fall short for many desperate patients in need. The UCSF team is on to an explanation for why. Focusing on colorectal and prostate cancer, these cancer brands seem largely impervious to a key mechanism of immunotherapy treatments. Apparently, a molecule known as PD-L1, doesn’t show up on the surface of all tumors. When this occurs, new immunotherapy drugs cannot interfere with the cancer signals. Follow the link below to read more about their findings.
Robert Blelloch, MD, Ph.D., associate chairman of the department of urology, UCSF